Kampman R, Nummikko-Pelkonen A, Kuha S
Acta Psychiatr Scand. 1978 Aug;58(2):142-8. doi: 10.1111/j.1600-0447.1978.tb06928.x.
The clinical efficacy of oral clomipramine and amitriptyline treatment (50--125 mg/day) was compared over a period of 2 months in 72 depressive patients visiting a psychiatric out-patient clinic. Both drugs were equally effective as measured by the Hamilton Rating Scale for Depression. According to a nurse's independent evaluation of 13 items the two drugs were equipotent in relieving depressive symptoms and no statistically significant differences between the treatment groups were found in the global evaluation by the investigator and the patient. A trend in favour of clomipramine was, however, seen in several parameters. The declines in the Hamilton Rating Scale scores and the nurse's evaluation scores were highly significant during the first 2 weeks of treatment (P less than 0.001) in both groups and the scores continued to decrease during the 2nd month of the study. The most common unwanted effects were dryness of the mouth and fatigue. The frequency of side effects was 51% in the clomipramine group and 43% in the amitriptyline group. The side effects were generally mild and transient and called for discontinuation of treatment in only one case in each group.
在一家精神科门诊就诊的72例抑郁症患者中,对口服氯米帕明和阿米替林治疗(50 - 125毫克/天)的临床疗效进行了为期2个月的比较。根据汉密尔顿抑郁量表测量,两种药物疗效相当。根据护士对13项指标的独立评估,两种药物在缓解抑郁症状方面效力相当,研究者和患者的整体评估中,治疗组之间未发现统计学上的显著差异。然而,在几个参数上发现了有利于氯米帕明的趋势。两组治疗的前2周内,汉密尔顿量表评分和护士评估评分的下降非常显著(P小于0.001),且在研究的第2个月评分继续下降。最常见的不良反应是口干和疲劳。氯米帕明组副作用发生率为51%,阿米替林组为43%。副作用一般较轻且为一过性,每组仅1例因副作用而停药。